Alerta

BLOOD BIOMARKERS IN LONG-COVID-19

Resumen de: US2025244326A1

A method of diagnosing long-COVID in a subject, the method comprising: (a) measuring the level of one or more biomarkers in a test sample obtained from the subject, and (b) comparing the level of the one or more biomarkers in the test sample with a healthy control and/or an acute COVID-19 reference level value of said one or more biomarkers, wherein an increase in the level of the one or more biomarkers in the test sample relative to the healthy control and/or acute COVID-19 reference level value of said one or more biomarkers is indicative of long-COVID diagnosis, and wherein the one or more biomarkers are selected from Table 5. In one embodiment, the one or more biomarkers include ANG-1, P-Sel and MMP-1. A method of treating long-COVID comprising administering to a subject one or more of the biomarkers are selected from Table 5.

METHODS OF ANALYZING SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2 (STNFR2) AND USES THEREOF

Resumen de: US2025244338A1

The present disclosure relates to methods of testing immunomodulatory activity of cells, including, for example, mesenchymal stem cells and uses of said cells that are determined as having immunomodulatory activity for treating COVID-19 related acute respiratory distress syndrome (ARDS). Disclosed herein are in vitro methods of evaluating mesenchymal stem cells for their effective immunomodulatory effects in vivo.

METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKING GALECTIN-3

Resumen de: US2025243282A1

Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.

NLRP3 INFLAMMASOME INHIBITORS AND COMPOSITIONS AND USES THEREOF

Resumen de: US2025243172A1

NLRP3 selective inhibitors (NSIs) as anti-inflammatory agents are provided, as are methods of using NSIs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, acute myocardial infarction, heart failure, arthritis, diabetes, gout, COVID-19, and autoinflammatory diseases.

MULTIEPITOPE SELF-ASSEMBLED NANOPARTICLE VACCINE PLATFORM (MSN-VACCINE PLATFORM) AND USES THERE OF

Resumen de: ZA202402732B

The present invention is drawn to a next generation nano vaccine platform by using structure- based design to utilize the conserved or less variable or highly immunogenic domains or epitopes and displaying it in a nano cage and produces it in as nanoparticle protein in prokaryotic expression system. The present invention is illustrated in detail by a vaccine design and construct for SARS CoV-2, SARS-CoV-2 variants, betacorona viruses, Monkey pox virus and Dengue virus.

PHARMACEUTICAL COMPOSITION COMPRISING CHLOROQUINE AND USES THEREOF

Resumen de: ZA202304380B

The present invention relates to pharmaceutical compositions comprising chloroquine and uses thereof. More specifically, the invention relates to a pharmaceutical composition comprising chloroquine or pharmaceutically acceptable salts thereof for use in the treatment or prevention of a viral lung infection, preferably caused by Betacoronavirus, including but not limited to 2019-nCoV (coronavirus), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV), wherein the pharmaceutical composition is administered by inhalation. The present invention provides an improved delivery into the lungs of a subject with minimum systemic exposure.

ANTIVIRAL SIRNA THERAPEUTIC FOR SARS-COV-2

Resumen de: AU2023347083A1

This disclosure relates to RNA interference (RNAi) reagents for treatment of SARS-CoV-2 infection, compositions comprising same, and use thereof to treat or prevent infection by SARS- CoV-2.

PROTECTIVE APPARATUSES FOR MINIMIZING RISK OF TRANSMISSION OF INFECTION AND ASSOCIATED SYSTEMS

Resumen de: EP4591823A2

Disclosed herein are protective apparatuses, and associated systems, for minimizing the risk of transmission of SARS-CoV-2 and/or other infectious diseases between individuals in close proximity to one another including, for example, transmission through droplets projecting from the mouth or nasal region of an infected individual. Said apparatuses may comprise a substantially transparent shield component and a handle component comprising a connecting aspect. The protective apparatuses may comprise light emitting diodes and associated control means. The protective apparatuses of the present disclosure may further comprise a camera communicatively connected to a display screen.

CORONAVIRUS VACCINE

Resumen de: ZA202406805B

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

Method for manufacturing SARS-CoV-2 autologous vaccine using recombinant SARS-CoV-2 lentiviral vector

Resumen de: KR20250115147A

본 발명은 재조합 SARS-CoV-2 렌티바이러스 벡터를 이용한 SARS-CoV-2 자가면역 백신의 제조방법에 관한 것으로, 구체적으로 본 발명은 SARS-CoV-2 바이러스의 항원 단백질을 암호화하는 폴리뉴클레오티드를 포함하는 수지상 세포에서 면역원성 항원 단백질의 발현을 유도하기 위한 재조합 렌티바이러스 벡터, 상기 본 발명의 재조합 렌티바이러스 벡터를 수지상 세포에 형질도입하는 단계를 포함하는, 수지상 세포 기반의 SARS-CoV-2 바이러스 감염증 예방용 백신 조성물의 제조방법 및 상기 방법으로 제조된 SARS-CoV-2 바이러스 감염증 예방용 백신 조성물에 관한 것이다.

SARS-CoV-2 broad-spectrum vaccine and application thereof

Nº publicación: CN120381512A 29/07/2025

Solicitante:

JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION PUBLIC HEALTH RES INSTITUTE OF JIANGSU
JIANGSU RUIKE BIOTECHNOLOGY CO LTD
ABZYMO BIOSCIENCES CO LTD
\u6C5F\u82CF\u7701\u75BE\u75C5\u9884\u9632\u63A7\u5236\u4E2D\u5FC3\uFF08\u6C5F\u82CF\u7701\u516C\u5171\u536B\u751F\u7814\u7A76\u9662\uFF09,
\u6C5F\u82CF\u745E\u79D1\u751F\u7269\u6280\u672F\u80A1\u4EFD\u6709\u9650\u516C\u53F8,
\u5317\u4EAC\u5B89\u767E\u80DC\u751F\u7269\u79D1\u6280\u6709\u9650\u516C\u53F8

Resumen de: CN120381512A

The invention provides an application of a fusion protein in preparation of an SARS-CoV-2 broad-spectrum vaccine, the fusion protein comprises an NTD structural domain and an RBD structural domain of an SARS-CoV-2 spike protein, provides more conservative epitopes, can effectively stimulate the generation of a neutralizing antibody, and can effectively inhibit the generation of the SARS-CoV-2 spike protein. The vaccine prepared by using the fusion protein can provide broad-spectrum and efficient protection for the SARS-CoV-2 wild type and various mutant strains; the invention also provides an application of the broad-spectrum vaccine as an immune enhancer, and also provides an immune kit under a corresponding immune strategy, the broad-spectrum vaccine can cooperate with other existing vaccines to enhance immunity, and can independently perform a complete immune procedure, and excellent immune protection can be provided in any way.